肝硬化门静脉血栓形成风险监测及抗凝管理*

doi:10.3969/j.issn.1672-5069.2024.01.002

Abstract

Jin Keke, Ding Huiguo. Risk and anticoagulation management of cirrhotic patients with portal vein thrombosis[J]. Journal of Practical Hepatology, 2024, 27(1): 3-6.

[1] Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis, 2021,22(4):176-186.
[2] Zhang Y, Xu B yan, Wang X bo, et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation. Clin Gastroenterol Hepatol, 2020,18(11):2564-2572.
[3] Zanetto A, Rodriguez-Kastro KI, Germani G, et al. Mortality in liver transplant recipients with portal vein thrombosis-an updated meta-analysis. Transpl Int, 2018,31(12):1318-1329.
[4] Nery F, Correia S, Macedo C, et al. Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. Aliment Pharmacol Ther, 2019,49(5):582-588.
[5] Rottenstreich A, Kleinstern G, Spectre G, et al. Thromboembolic events following splenectomy: Risk factors, prevention, management and outcomes. World J Surg, 2018,42(3):675-681.
[6] Liao Z, Wang Z, Su C, et al. Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis. PLoS One, 2023,18(8):e0290164.
[7] Danno K, Ikeda M, Sekimoto M, et al. Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy. Surgery, 2009,145(5):457-464.
[8] Huang D, Tao M, Cao L, et al. Risk factors and anticoagulation effects of portal vein system thrombosis after laparoscopic splenectomy in patients with or without cirrhosis. Surg Laparosc Endosc Percutan Tech, 2019,29(6):498-502.
[9] Lin Y, Cai X, Hong H, et al. Risk factors of portal vein system thrombosis after splenectomy: a meta-analysis. ANZ J Surg, 2023,10.1111/ans.18633.
[10] Villa E, Bianchini M, Blasi A, et al. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol, 2022,76(5):1151-1184.
[11] Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021,73(1):366-413.
[12] O’Leary JG, Greenberg CS, Patton HM, et al. AGA Clinical Practice Update: Coagulation in cirrhosis. Gastroenterology, 2019,157(1):34-43.
[13] Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology, 2018,155(3):705-718.
[14] Loffredo L, Violi F. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. Dig Liver Dis, 2019,51(1):24-27.
[15] Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut, 2018,67(10):1870-1880.
[16] Zanetto A, Campello E, Bulato C, et al. Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. JHEP Rep, 2022,4(7):100493.
[17] Nocella C, Carnevale R, Bartimoccia S, et al. Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. Thromb Haemost, 2017,117(08):1558-1570.
[18] Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol, 2017,67(5):950-956.
[19] Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program, 2015,2015(1):243-249.
[20] Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost, 2021,19(4):1116-1122.
[21] Sinegre T, Duron C, Lecompte T, et al. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. J Thromb Haemost, 2018,16(6):1132-1140.
[22] La Mura V, Tripodi A, Tosetti G, et al. Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. Liver Int, 2016,36(9):1322-1330.
[23] Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology, 2009,137(6):2105-2111.
[24] Sheen CL, Lamparelli H, Milne A, et al. Clinical features, diagnosis and outcome of acute portal vein thrombosis. QJM, 2000,93(8):531-534.
[25] Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010,51(1):210-218.
[26] De Gaetano AM, Lafortune M, Patriquin H, et al. Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography. AJR, 1995,165(5):1151-1155.
[27] Girleanu I, Stanciu C, Cojocariu C, et al. Natural course of nonmalignant partial portal vein thrombosis in cirrhotic patients. Saudi J Gastroenterol, 2014,20(5):288-292.
[28] Yokoyama S, Ishizu Y, Honda T, et al. Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis. Hepatology Res, 2022,52(2):199-209.
[29] Driever EG, Von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology, 2022,75(4):898-911.
[30] Berzigotti A, García-Criado Á, Darnell A, et al. Imaging in clinical decision-making for portal vein thrombosis. Nat Rev Gastroenterol Hepatol, 2014,11(5):308-316.
[31] Sherman CB, Behr S, Dodge JL, et al. Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria. Liver Transpl, 2019,25(2):207-216.
[32] Scheiner B, Stammet PR, Pokorny S, et al. Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wien Klin Wochenschr, 2018,130(13-14):446-455.
[33] Gao Z, Li S, Zhao J, et al. Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial. Intern Emerg Med, 2023,18(2):513-521.
[34] Pettinari I, Vukotic R, Stefanescu H, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol, 2019,114(2):258-266.
[35] Cerini F, Gonzalez JM, Torres F, et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology, 2015,62(2):575-583.
[36] Guerrero A, Campo LD, Piscaglia F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis. J Hepatol, 2023,79(1):69-78.
[37] De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII-renewing consensus in portal hypertension. J Hepatol, 2022,76(4):959-974.

Risk and anticoagulation management of cirrhotic patients with portal vein thrombosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhao Yuwen, Zhu Chuanlong. Management of malnutrition and sarcopenia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(3): 324-328.
[2]	Wu Dahai, Liu Qilin, Lu Jiefu, et al. Changes of serum neutrophil extracellular trap markers in patients with hepatitis B liver cirrhosis complicated by portal vein thrombosis [J]. Journal of Practical Hepatology, 2024, 27(3): 394-397.
[3]	Ding Rong, Ji Wenli, Chen Tingting, et al. Distribution and drug resistance of pathogens in patients with decompensated hepatitis B cirrhosis and spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2024, 27(3): 398-401.
[4]	Li Julan, Zhang Huatang, Zheng Yijuan, et al. Chinese herbal medicine compound,Fuzheng Huayu table, ameliorate liver fibrosis in patients with hepatitis B-induced liver cirrhosis receiving entecavir antiviral treatment [J]. Journal of Practical Hepatology, 2024, 27(3): 402-405.
[5]	Cai Junling, Su Li, Hao Li, et al. Efficacy of antiviral therapy based on sorfosbuvir combination in the treatment of patients with hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(3): 406-409.
[6]	Wang Xiuqi, Zhang Yu, Wu Yifan, et al. Clinical features and risk factors of hepatic myelopathy after TIPS for in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2024, 27(3): 410-413.
[7]	Zhu Chunfen, Ren Chunlin, Guo Xia. Clinical feature, electrocardiogram findings and risk factors in patients with cirrhotic cardiomyopathy [J]. Journal of Practical Hepatology, 2024, 27(3): 414-417.
[8]	Wang Qianwen, Hu Linlin, Xu Yunjun. Diagnostic performance of serum SPINK1 levels for hepatocellular carcinoma in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(3): 442-445.
[9]	Shi Ameng, He Xin, Wang Ying, et al. Prevalence and risk factors of gallstones in non-obese individuals for physical examination [J]. Journal of Practical Hepatology, 2024, 27(3): 458-461.
[10]	Xu Jinghang, Yu Yanyan, Xu Xiaoyuan. Liver cirrhosis: Current state of the art [J]. Journal of Practical Hepatology, 2024, 27(2): 161-164.
[11]	Zhang Shuqian, Xie Wen. Definition, detection and clinical application of effective albumin [J]. Journal of Practical Hepatology, 2024, 27(2): 165-168.
[12]	Zhang Tianqi, Wang Min, Yang Na, et al.. Drug-induced liver injury in ICU patients with severe infection receiving tigecycline therapy: An analysis of 74 cases [J]. Journal of Practical Hepatology, 2024, 27(2): 214-217.
[13]	Li Yao, Liang Jian, Zhang Chun, et al.. Clinical efficacy of entecavir and peginterferon-α2b combination in treatment of patients with compensated hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(2): 226-229.
[14]	Wang Hongxia, Xu Xiaoqian, Yu Mingshuai. Anesthesia of different concentrations of oxycodone and target-controlled infusion of propofol combination in patients with hepatitis B liver cirrhosis and esophageal variceal bleeding undergoing endoscopic sclerotherapy [J]. Journal of Practical Hepatology, 2024, 27(2): 230-233.
[15]	Wan Guixiang, Li Zhonglian, Zhao Yabo, et al.. Efficacy of entecavir and herbal compound combination in the treatment of patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(2): 234-237.